Diametric Capital, LP Ocuphire Pharma, Inc. Transaction History

Diametric Capital, LP

$118 Million
Q4 2024

A detailed history of Diametric Capital, LP transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Diametric Capital, LP holds 29,299 shares of OCUP stock, worth $28,713. This represents 0.02% of its overall portfolio holdings.

Number of Shares

29,299

Previous 33,251 11.89%

Holding current value

$28,713

Previous $43,000 34.88%

% of portfolio

0.02%

Previous 0.02%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$0.88 - $1.35 $3,477 - $5,335	-3,952 Reduced 11.89%	29,299 $28,000
Q3 2024 Nov 13, 2024	SELL	$1.19 - $2.07 $5,692 - $9,902	-4,784 Reduced 12.58%	33,251 $43,000
Q2 2024 Aug 13, 2024	SELL	$1.51 - $2.23 $20,172 - $29,790	-13,359 Reduced 25.99%	38,035 $58,000
Q1 2024 May 15, 2024	SELL	$1.89 - $3.27 $41,460 - $71,733	-21,937 Reduced 29.92%	51,394 $103,000
Q4 2023 Feb 13, 2024	BUY	$2.59 - $3.64 $44,734 - $62,870	17,272 Added 30.81%	73,331 $220,000
Q3 2023 Nov 14, 2023	BUY	$3.35 - $4.33 $93,284 - $120,573	27,846 Added 98.7%	56,059 $187,000
Q2 2023 Aug 11, 2023	SELL	$3.63 - $6.38 $99,589 - $175,035	-27,435 Reduced 49.3%	28,213 $122,000
Q1 2023 May 11, 2023	BUY	$3.01 - $3.85 $96,470 - $123,392	32,050 Added 135.82%	55,648 $208,000
Q4 2022 Mar 29, 2023	SELL	$2.04 - $3.53 $1,938 - $3,353	-950 Reduced 3.87%	23,598 $83,000
Q3 2022 Nov 14, 2022	SELL	$1.82 - $2.79 $17,850 - $27,364	-9,808 Reduced 28.55%	24,548 $49,000
Q2 2022 Aug 15, 2022	SELL	$1.8 - $3.25 $30,915 - $55,818	-17,175 Reduced 33.33%	34,356 $66,000
Q1 2022 May 16, 2022	SELL	$2.75 - $4.39 $104,255 - $166,429	-37,911 Reduced 42.39%	51,531 $166,000
Q4 2021 Feb 14, 2022	BUY	$3.4 - $5.19 $304,102 - $464,203	89,442 New	89,442 $334,000

Others Institutions Holding OCUP

# of Institutions

Shares Held

5.21M

Call Options Held

12.6K

Put Options Held

1.8K

View Full List

About Ocuphire Pharma, Inc.

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $20.2M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

More about OCUP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Diametric Capital, LP with notifications on news.

Account

Diametric Capital, LP Ocuphire Pharma, Inc. Transaction History